title: Cisplatin and etoposide in advanced colorectal carcinoma.
abstract: The cisplatin (P) and etoposide (E) combination has been found to be active in several types of solid tumors. It has never been previously tested in advanced colorectal cancer. Thirty-three patients with advanced colorectal cancer were treated with this combination. Five patients responded (1 complete and 4 partial responses) with an overall response rate of 15% (95% confidence limits, 3%-27%). Responses were seen in both untreated (3/16) and pretreated (2/17) patients. The median duration of response was 28 weeks (range: 23; 80), the median time to progression was 16 weeks (range 2; 80) and the median survival time for all entered patients was 38 weeks (range: 2; 187+). These results suggest that the PE combination has a low but definite activity in advanced colorectal carcinoma, particularly in previously untreated patients.
authors.affiliation: Medical Oncology Service, Ospedale Regionale, Parma, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Passalacqua
authors.forename: G
authors.initials: G
authors.lastname: Bisagni
authors.forename: G
authors.initials: G
authors.lastname: Cocconi
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: B
authors.initials: B
authors.lastname: Di Blasio
authors.forename: G
authors.initials: G
authors.lastname: Ceci
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
chemical_list: D005047:Etoposide; D002945:Cisplatin